SCHEMBL612008

SCHEMBL612008

COC(=O)c1ccc(-c2ccncc2NCc2ccccc2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 0.51
KDM6B O15054 2/20 0.51
KDM4E B2RXH2 1/20 0.51
KDM4A O75164 1/20 0.51
KDM4D Q6B0I6 1/20 0.51
KDM5B Q9UGL1 2/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
FAAH O00519 1/20 0.44
IL2 P60568 1/20 0.43
BRS3 P32247 1/20 0.41
KDM5A P29375 1/20 0.41
CDC7 O00311 1/20 0.41
DBF4 Q9UBU7 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
HDAC1 Q13547 2/20 0.39
CYP3A4 P08684 1/20 0.39
ADRA2C P18825 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1725901 0.91 KDM4C (0.59) KDM4CKDM6BKDM4EKDM4AKDM4D
SCHEMBL1725706 0.85 IL2 (0.47) KDM4CKDM6BKDM4EFAAHIL2
SCHEMBL613989 0.83 KDM6B (0.49) KDM4CKDM6BKDM4EIL2MKNK1
SCHEMBL1724875 0.81 KDM4C (0.51) KDM4CKDM6BKDM4EFAAHIL2
SCHEMBL614603 0.81 IL2 (0.49) KDM4CKDM4EFAAHIL2MKNK1
SCHEMBL1724787 0.78 IL2 (0.47) KDM4CKDM4EIL2MKNK1MKNK2
SCHEMBL1725204 0.77 MKNK1 (0.49) KDM4CKDM6BKDM4EIL2MKNK1
SCHEMBL1724418 0.75 KDM4C (0.58) KDM4CKDM6BKDM4EIL2MKNK1
SCHEMBL6197819 0.75 HDAC1 (0.60) CA1CA2FAAHHDAC1CYP3A4
SCHEMBL1523353 0.74 KDM4C (0.62) KDM4CKDM6BKDM4EKDM4AKDM4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK KDM4C 1474/4885KDM6B 673/4885KDM4E 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.